Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
77
resultados
Última actualización
17/01/2026 [06:45:00]
Resumen de: US20260015406A1
The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.
Resumen de: US20260014226A1
The invention is directed to room temperature stable injectable formulations of carfilzomib or its pharmaceutically acceptable derivatives thereof in the form of ready to dilute solution and concentrates with no hemolytic potential. Further the invention is directed to a method for treating patients with relapsed or refractory multiple myeloma by administering such composition.
Resumen de: US20260014252A1
The present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the antigen-binding molecules are bispecific antibodies or antigen-binding fragments thereof that comprise a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the bispecific antibodies are useful for treating a cancer (e.g., multiple myeloma).
Resumen de: WO2026015344A1
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.
Resumen de: WO2026015729A1
The present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the antigen-binding molecules are bispecific antibodies or antigen-binding fragments thereof that comprise a first antigen-binding domain that binds specifically to GPRC5D and a second antigen-binding domain that binds specifically to CD28. In certain embodiments, the bispecific antibodies are useful for treating a cancer (e.g., multiple myeloma).
Resumen de: US20260015421A1
Described are γδ T-cells that express a non-signaling chimeric antigen receptor (CAR), wherein the CAR binds a tumor antigen such as CD19 or CD33. Also described are pharmaceutical compositions thereof and the method for the treatment of cancer such as leukemia.
Resumen de: US20260014255A1
The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.
Resumen de: US20260014129A1
The invention relates to the treatment of chronic myeloid leukemia (CML). In particular it relates to the treatment of CML with inhibitors of mitochondrial pyruvate transport, which are able to target leukemic stem cells (LSCs) which are resistant to therapy with tyrosine kinase inhibitors (TKIs). Combination therapies with BCR-ABL kinase inhibitors are also described.
Resumen de: WO2026015480A1
This invention pertains to fusion protein mutants comprising a Prime Editing enzyme having a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence comprises a SpCas9 H840A nickase mutant protein of SEQ ID NO:152 and the second amino acid sequence comprises a Moloney Murine Leukemia Virus reverse transcriptase protein mutant (MMLV RTase mutant), wherein the fusion protein mutant displays at least the equivalent or greater activity of a reference Prime Editing enzyme in genome editing.
Resumen de: AU2024275661A1
The present disclosure is concerned with compounds that restore p53 activity and methods of using the compounds in the treatment of various disorders related to loss of p53 activity such as, for example, cancer (e.g, a sarcoma, a carcinoma, a head-and-neck cancer, hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: WO2026012487A1
Provided is a bispecific CAR-T cell targeting BCMA and GPRC5D. Specifically, provided is an autologous CAR-T cell targeting both BCMA and GPRC5D antigen molecules and expressing chimeric antigen receptors (CARs) in parallel. Also provided is a use of a CAR-T cell for adoptive T-cell therapy for diseases including multiple myeloma.
Resumen de: EP4678190A1
The present disclosure discloses a use of anti-CD20 antibody drug conjugate (ADC) in the preparation of a drug for treating Mantle Cell Lymphoma (MCL). The drug has good clinical efficacy in treating relapsed or refractory mantle cell lymphoma (R/R MCL), is safe and controllable, and meets the currently unmet clinical needs.
Resumen de: EP4678191A1
The present disclosure discloses a use of anti-CD20 ADC in the preparation of a drug for treating NHL, and the drug has excellent clinical efficacy and safety in treating a R/R NHL patient after receiving at least two standard treatments.
Resumen de: AU2024302737A1
The present disclosure provides for a chimeric antigen receptor (CAR) polypeptide comprising a CD74 antigen binding domain, a transmembrane domain, an intracellular signaling domain, and a co-stimulatory signaling region. Further provided herein is an isolated nucleic acid encoding the recombinant polypeptide as disclosed herein, a vector comprising the isolated nucleic acid, and a cell comprising the vector. Also provided herein is a method of treating lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the chimeric antigen receptor polypeptide as disclosed herein. Further described herein is a method of reducing tumor activity in a subject with lymphoma, the method comprising administering to the subject a therapeutically effective amount of the chimeric antigen receptor polypeptide as described herein.
Resumen de: AU2024279967A1
The present disclosure relates to CD19 CAR-T cell products and methods of treating relapsed or refractory CD19+ haematological malignancies.
Resumen de: WO2026007901A1
The present invention relates to an FLT3-CAR-γδT cell co-expressing a cytokine and a use thereof. Specifically, the present invention provides an engineered CAR-γδT cell targeting FLT3, wherein the CAR-γδT cell co-expresses an IL-2 or IL-7 cytokine, maintains a high stemness level and proliferation capacity, and has a sustained tumor cell killing ability. The FLT3-CAR-γδT cell co-expressing a cytokine of the present invention demonstrates persistent killing ability and anti-tumor activity against acute myeloid leukemia (AML) tumor cells in multiple in vitro and in vivo experiments, has high safety and wide applicability, and has application prospects in the field of AML therapy.
Resumen de: WO2026007411A1
An anti-IL1RL1/IL-33/NF-kB antibody and a method for treating acute myeloid leukemia using same. The anti-IL1RL1/IL-33/NF-kB antibody comprises an anti-IL1RL1 antibody, an anti-IL-33 antibody, and an anti-NF-kB antibody. The treatment method comprises: step 1, patient assessment and diagnosis; step 2, antibody selection and preparation; step 3, treatment plan formulation; step 4, antibody administration; step 5, efficacy monitoring and assessment; and step 6, subsequent treatment and follow-up. The combined use of the anti-IL1RL1 antibody, the anti-IL-33 antibody, and the anti-NF-kB antibody for treating AML can inhibit the proliferation and survival of AML cells at multiple levels by means of simultaneously blocking the IL-33/IL1RL1 signaling pathway and NF-kB activation, thereby improving the therapeutic effect.
Resumen de: WO2026007326A1
A compound as shown in general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, and the use thereof in cancer-related diseases such as acute myeloid leukemia. The synthesized vinblastine derivative has an antiproliferative activity against acute myeloid leukemia cancer cells that is significantly superior to that of vinblastine, can be used as a toxin molecule in the development of antibody-drug conjugates, and has a great anti-tumor effect.
Resumen de: US20260009797A1
The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.
Resumen de: US20260007675A1
Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.
Resumen de: US20260008862A1
B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.
Resumen de: US20260007767A1
The present disclosure relates to anti-SCUBE1 antibodies, antigen-binding fragments thereof, and antibody drug conjugates (ADCs), as well as methods of treating and/or preventing SCUBE1-expressing cancers.
Resumen de: MX2025014342A
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a GPRC5DxCD3 bispecific antibody on a monthly dosing schedule.
Resumen de: MX2025014558A
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Nº publicación: MX2025012459A 07/01/2026
Solicitante:
JANSSEN BIOTECH INC [US]
JANSSEN BIOTECH, INC
Resumen de: MX2025012459A
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a BCMAxCD3 bispecific antibody and a GPRC5DxCD3 bispecific antibody to the subject.
BOPI
Sede Electrónica
